Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
22 November 2022 - 11:00PM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company, today announced that
Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of
Atea Pharmaceuticals, together with other members of the Atea
management team, will participate in a fireside chat and present a
business update at the 5th Annual Evercore ISI HealthCONx
Conference on Tuesday, November 29 at 9:40 a.m. ET.
A live webcast of the presentation will be available here and on
the Company’s website at https://ir.ateapharma.com/. An archived
webcast will be available on Atea Pharmaceuticals’ website for at
least 90 days following the event.
About Atea Pharmaceuticals
Atea is a clinical stage biopharmaceutical company focused on
discovering, developing and commercializing oral therapies to
address the unmet medical needs of patients with severe diseases.
Leveraging the Company’s deep understanding of antiviral drug
development, nucleos(t)ide chemistry, biology, biochemistry and
virology, Atea has built a proprietary nucleos(t)ide prodrug
platform to develop novel product candidates to treat single
stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent
cause of severe viral diseases. Atea plans to continue to build its
pipeline of antiviral product candidates by augmenting its
nucleos(t)ide platform with other classes of antivirals that may be
used in combination with its nucleos(t)ide product candidates.
Currently, Atea is focused on the development of orally-available
antiviral agents for difficult-to-treat, severe viral infections,
including severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus
(HCV), dengue virus and respiratory syncytial virus (RSV). For more
information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding our expectations surrounding the potential of our product
candidates, including bemnifosbuvir combination product candidates,
and expectations regarding our pipeline, including trial design and
development timelines. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
uncertainty around and costs associated with the clinical
development of bemnifosbuvir as a potential treatment for COVID-19
and HCV and clinical development of AT-752 for dengue. These and
other important factors discussed under the caption “Risk Factors”
in our Annual Report on Form 10-K for the year ended December 31,
2021 and our other filings with the SEC could cause actual results
to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Apr 2023 to Apr 2024